DUBLIN, Nov. 9, 2021 /PRNewswire/ -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The 'RAS Targeting Therapies Market Report' features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, over the next decade. Further, the study underlines an in-depth analysis of players engaged in the development of RAS targeting therapies.
Moreover, post the onset of the COVID-19 pandemic, the treatment of cancer patients has become arduous, as patient visits are being cancelled by healthcare facilities in order to preserve resources and prevent patients from getting infected with SARS-CoV-2. Further, as per the National Cancer Institute, the delay in screening and treatment of cancer patients due to the COVID-19 pandemic is likely to result in 10,000 deaths, which could have been otherwise prevented, over the next decade.
One of the key objectives of the report was to estimate the existing market size and future growth potential associated with RAS targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely annual treatment cost of RAS targeting therapies, we have developed informed estimates on the evolution of the market over the coming decade.
In order to account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
Overview
Given the complexities associated with conventional cancer treatment options, such as chemotherapy and radiation therapy, drug developers engaged in this domain have shifted their focus on the development of drugs against specific oncogenic mutations that are primarily responsible for the disease development and/or progression.
It is worth mentioning that one such target (RAS), which was previously considered undruggable, was found to be associated with 30% of cancers in humans. Over the years, several drug candidates have been evaluated to target specific RAS mutated genes. In 2021, LUMAKRAST (sotorasib), a RAS targeting small molecule was approved by the USFDA for the treatment of metastatic non-small cell lung cancer in patients with KRAS G12C mutations.
Given its high efficacy and good safety profile, significant efforts are being made to evaluate the potential of the aforementioned drug across multiple solid tumor indications, such as colorectal cancer. Presently, several companies (including big pharma players), independently or in collaboration with other stakeholders, are actively engaged in the development of RAS targeting therapies.
Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.
Key Questions Answered
- Which are the key candidates being developed at preclinical and clinical stages of development?
- What are the key therapeutic indications for which RAS targeting therapies are being investigated?
- What are the key challenges faced by stakeholders engaged in this domain?
- Who are the leading industry and non-industry players engaged in the development of RAS targeting therapies?
- What are the key geographies where research focused on RAS mutated cancer is being conducted?
- Who are the key investors in this domain?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the key value drivers that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of RAS Targeting Therapies
3.2. Approaches Used to Target Mutated RAS Gene
3.3. Historical Notable Developments
3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers
4. CURRENT MARKET LANDSCAPE
4.1. RAS Targeting Therapies: Pipeline Review
4.2. RAS Targeting Therapies: Developer Landscape
5. CLINICAL TRIALS AND ENDPOINT ANALYSIS
5.1. RAS Targeting Therapies: List of Clinical Trials
5.1.1. Analysis by Trial Status
5.1.2. Analysis by Trial Registration Year
5.1.3. Analysis by Type of Masking
5.1.4. Analysis by Type of Intervention Model
5.1.5. Analysis by Study Design
5.1.6. Analysis by Type of Sponsor
5.1.7. Most Active Players: Analysis by Number of Trials Registered
5.1.8. Analysis by Trial Registration Year and Geography
5.1.9. Analysis by Type of Target Indication
5.1.10. Analysis by Enrolled Patient Population
5.1.11. Analysis of Enrolled Patient Population by Geography
5.1.12. Analysis of Number of Clinical Trials by Geography
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Product Competitiveness: North America
6.2. Product Competitiveness: Europe
6.3. Product Competitiveness: Asia-Pacific
7. COMPANY PROFILES
7.1. Amgen
7.1.1. Company Overview
7.1.2. Financial Information
7.1.3. Portfolio of RAS Targeting Therapies
7.1.4. Recent Developments and Future Outlook
7.2. GlobeImmune
7.3. Jacobio Pharmaceuticals
7.4. Mirati Therapeutics
7.5. Novartis
7.6. Onconova Therapeutics
7.7. Targovax
7.8. Verastem Oncology
8. PUBLICATION ANALYSIS
8.1. RAS Targeting Therapies: Recent Publications
8.1.1. Analysis by Year of Publication
8.1.2. Analysis by Type of Publication
8.1.3. Analysis by Study Objective
8.1.4. Analysis by Emerging Focus Areas
8.1.5. Analysis by Target Therapeutic Area
8.1.6. Analysis by Target Gene
8.1.7. Analysis by Target Indication
8.1.8. Analysis by Affiliation of First Author
8.1.9. Leading Players: Analysis by Number of Publications
8.1.10. Key Journals: Analysis by Number of Publications
9. PARTNERHSIPS AND COLLABORATIONS
9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Type of Partner
9.1.4. Analysis by Type of Molecule
9.1.5. Most Active Players: Analysis by Number of Partnerships
9.1.6. Most Active Partners: Analysis by Number of Partnerships
9.1.7. Regional Analysis
9.1.8. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. RAS Targeting Therapies: Funding and Investments
10.1.1. Analysis by Number of Funding Instances
10.1.2. Analysis by Amount Invested
10.1.3. Analysis by Type of Funding
10.1.4. Most Active Players: Analysis by Amount Raised
10.1.5. Most Active Investors: Analysis by Number of Instances
10.1.6. Analysis by Geography
11. KEY COMMERCIALIZATION STRATEGIES
11.1. Successful Drug Launch Strategy: Publisher Framework
11.2. Successful Drug Launch Strategy: Product Differentiation
11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapie
11.5. Strategies Adopted During / Post Therapy Approval
11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Forecast Methodology and Key Assumptions
12.2. Global RAS Targeting Therapies Market, 2021-2031
12.3. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Target Indication
12.4. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Molecule
12.5. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Therapy
12.6. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Route of Administration
12.7. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Geography
12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
12.8.1. LUMAKRASTM (Amgen): Sales Forecast
12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
12.8.3. AMO-01 (AMO Pharma): Sales Forecast
12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
12.8.5. Binimetinib (Array Biopharma): Sales Forecast
12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
12.8.7. LXH274 (Novartis): Sales Forecast
12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
12.8.10. TG01 (Targovax): Sales Forecast
12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
12.8.12. siG12D (Silenseed): Sales Forecast
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/vo8a60
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:SOURCE Research and Markets
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
